Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: IPF and Learning Tech hire CFOs from Provident, SIG

Tue, 09th Nov 2021 14:18

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

International Personal Finance PLC - Leeds-based provider of digital and home credit personal loans - Hires Gary Thompson as chief financial officer and board director, starting on April 4 next year. Thompson is finance director of Vanquis Bank Ltd, a subsidiary of Provident Financial PLC.

----------

Learning Technologies Group PLC - technology and services for digital learning and talent management, based in London - Hires Kath Kearney-Croft as CFO, starting immediately. Kearny-Croft most recently was interim CFO of building materials firm SIG PLC.

----------

Sound Energy PLC - gas developer in Morocco - Richard Liddell resigns as senior independent director, leaving the board on November 30. Liddell has been on the board since 2015 and served a term as chair. Sound Energy will appoint an additional independent non-executive director "in due course".

----------

James Cropper PLC - paper products manufacturer based in Cumbria - Hires Sarah Miles and Martin Court as non-executive directors, starting Tuesday. Miles is chief executive officer of Feelunique.com, which sells beauty products. She previously held executive roles at retailer Amazon.com Inc and distiller Diageo PLC. Court is chief commercial officer and an executive director of polymer firm Victrex PLC. Meanwhile, Andrew Hosty is stepping down as a non-executive director this month, having served three years on the board.

----------

nanosynth group PLC - London-based digital monitoring and safeguarding systems manufacturer formerly known as Remote Monitored Systems - Chair Antony Legge resigns from board immediately "to pursue other business interests". Richard Clarke to take over as interim chair while the board looks for a replacement for Legge.

----------

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Non-Executive Chair Alastair Riddell will become executive chair from December 1. Nuformix has been without a CEO since July. At the time, Riddell wrote a letter to shareholders to address the "frustration and confusion" that followed the announcement that Anne Brindley was leaving as CEO, having only joined Nuformix in December. Riddell had said the departure was "no reflection on Nuformix or her view of the opportunities in the Nuformix pipeline".

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.